Whether autophagy and lysosomal impairment are contributors or a consequence of tauopathy is unclear [154,159], but many studies have shown evidence that pharmacological enhancement of autophagy activity in patient-derived neurons and in vivo can reduce oligomeric and aggregated tau, mitigate tau neuronal transmission, and reduce cell loss, supporting a role for autophagy modulators in therapeutics [159,193,206,207,208,211,212,213,215,216,217]. This evidence concerns the gene MAPT and tauopathy.